Latest From Biotech Now

Despite Opposition from the Scientific Community, Efforts to Label GMOs Continue

Ag Biotech: Going on the Offense

The editors of Scientific American™ have notably compiled several firm arguments to counter support for labeling of foods made from genetically modified organisms (GMOs).  In their recent editorial titled, Label for GMO Foods Are a Bad Idea, Scientific American™ has successfully demonstrated how GMO labeling limits consumer choice, how foods containing GM ingredients can provide consumers with vital nutrients and how GMOs can be less costly to their conventional counterparts.  Here is a sample of Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , ,

State Legislation Needed For Substitution of Interchangeable Biologics

Copyright sanofi pasteur

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to mention a key issue in the biosimilars debate. This bill – or legislation similar to it – is essential to allow for the eventual substitution of interchangeable biologic therapies in the state of California. State laws governing prescription drug substitution were written before the advent of biosimilars and do not take the complexity of biologics into account. California, along with Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Golden Rice Petition Draws 5,000+ Supporters

golden-rice3-115x76

If the authors of the Change.org petition condemning the destruction of Golden Rice field trials intended for the outrage to go viral, they have succeeded.  As this blog is posted, 5,239 people have signed onto the petition – most from the scientific community and added their comments urging that scientific advances not be impeded by uninformed activists. In addition, the furor in the media arena and blogosphere continues. Mark Lynas, UK-based environmentalist and former anti-GMO Read More >

Farmer Gene  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,

New FDA Final Guidance on Clinical Trial Institutional Review Boards

clinical-trials

On Tuesday, August 27th, the FDA finalized its Guidance for Institutional Review Boards, Clinical Investigators and Sponsors on Institutional Review Board Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an Investigational New Drug/Investigational Device Exemption is Needed.  In an article published earlier today, the Pink Sheet’s Sarah Karlin summarized the goals of this guidance as strengthening human subject protection during clinical research and increasing the efficiency of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

What a Patent is Not

shutterstock_2103563

‘Patent trolls.’  ‘Patients over patents.’  ‘Do Not Patent My Genes.’  ‘Patents ate my baby.’  Ok, so I made the last one up.  The emphasis on patents in the public discourse has reached a new high.  Yet, many commentators get the basics wrong.  Here are a few things that a patent is not. A patent is not ownership of a thing, whether it is life, genes, viruses, computer code, or any other animate or inanimate object.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,